ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2025
One year follow up of descemet stripping only: corneal tomography changes and visual acuity outcomes.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDescemet Stripping Only (DSO) is a minimally invasive procedure for Fuchs' Endothelial Corneal Dystrophy (FECD) that leverages peripheral endothelial regeneration without donor tissue. This study evaluates visual and anatomical outcomes of DSO and the role of guttae distribution in recovery.
methodsA prospective study included 30 eyes of FECD patients undergoing DSO. Patients were classified by guttae distribution: type A (central) or type B (0º-180º meridian). Preoperative and postoperative outcomes, including corrected distance visual acuity (CDVA), central corneal thickness (CCT), and endothelial cell density (ECD), were assessed over 12 months.
resultsOf 26 patients completing follow-up, 42.31% achieved a CDVA ≥ 0.22 logMAR by week 4, and 84.62% by month 12. Type B patients recovered faster, reaching CDVA ≥ 0.10 logMAR in 56 days versus 112 days for type A. Mean CCT improved from 606.96 ± 60.97 μm to 550.40 ± 29.67 μm (p = 0.0001). Postoperative ECD averaged 1402.7 ± 130.56 cells/mm². Corneal densitometry improved significantly but remained higher than controls.
conclusionsDSO is an effective treatment for FECD with adequate peripheral endothelial reserve. Guttae distribution affects recovery speed, but final outcomes are similar. If no improvement occurs by the third month, a rescue DMEK is effective. Keratometry remains unchanged, epithelial thickness slightly increases, and corneal densitometry improves postoperatively. KEY MESSAGES: What is know: DSO is a donor-free surgical option for endothelial dystrophies like Fuchs' dystrophy, utilizing the eye's natural endothelial regenerative capacity in selected patients. Success relies on residual endothelial cell density and biomarkers like preoperative corneal thickness to predict regeneration outcomes. WHAT IS NEW: Pattern of guttae distribution influences recovery timeline in DSO: Patients with type B guttae distribution (0º-180º meridian) achieve a CDVA of 0.1 logMAR faster than those with type A (central guttae), though finalvisual acuity, pachymetry, and endothelial cell density are similar at 12 months. DSO as an effective treatment for fuchs' endothelial corneal dystrophy: Descemet stripping only achieves corneal clearance in most cases within 3-4 months, with significant CDVA and quality of life improvements (NEI VFQ-25 scores), supporting its role as a minimally invasive alternative to donor graft surgeries.
Indexed as
Identifiers
40325211What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.